PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Metabolic bone disease

Drugs in development · updated 30 October 2026

Metabolic bone disease: drugs in development

As of 30 October 2026 there are 5 active clinical trials (recruiting or ongoing, phases I–III) on 4 drugs for metabolic bone disease. One is experimental, that is not yet approved in the United States.

5Active trials
1Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
VeverimerI1NCT07473713

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
RisedronateAtelvia®, Actonel®III1NCT04922333
EverolimusRAD001, EveroliumusII2NCT06789900
SemaglutideWegovy, RybelsusII1NCT06050577

Sorted by most advanced phase and number of active trials.

All 4 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001851 “Bone Diseases, Metabolic”.

ItalianoFrançaisDeutsch